EUVIMEDEUVIMED entdecken
Crossref

A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14

Shuwei Gao, Yanqiu Wei, Chen Li, Bingbing Xie, Xinran Zhang, Ye Cui iD, Huaping Dai iD

American Journal of Physiology-Cell Physiology · 2025

DOI: 10.1152/ajpcell.00374.2024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2025. Verfasst von Shuwei Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: | Natural Science Foundation of Beijing Municipality (), MOST | National Key Research and Development Program of China (NKPs), CAMS Insitute of Respiratory Medicine Grant for Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the present study, our data first reveal that a novel lncRNA ABCE1-5 could inhibit pulmonary fibrosis through interacting with krt14 and negative regulation of its expression, and indicated ABCE1-5 also regulates the phosphorylation of mTOR and Akt, thus acting on extracellular matrix remodeling in lung fibrosis procession. These results suggest that novel molecules within the ABCE1-5-krt14-mTOR axis may serve as potential candidates for clinical application in IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingIdiopathic Pulmonary FibrosisHumansAnimalsMiceMaleA549 CellsBleomycinSignal TransductionMice, Inbred C57BLLungApoptosisCell MovementTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktDisease Models, Animal

Stichwörter der Autor:innen

ABCE1-5Krt-14long-noncoding RNAmTORpulmonary fibrosis

Substanzen

RNA, Long NoncodingBleomycinTOR Serine-Threonine KinasesProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • National Center for Respiratory Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • National Clinical Research Center for Respiratory Diseases, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Department of Clinical Research and Data Management, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Department of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, People's Republic of China.

ORCID-Profile: Ye Cui, Huaping Dai

Förderung

  • | Natural Science Foundation of Beijing Municipality ()
  • MOST | National Key Research and Development Program of China (NKPs)
  • CAMS Insitute of Respiratory Medicine Grant for Young Scholars
  • 北京市科学技术委员会 | Natural Science Foundation of Beijing Municipality

Zitieren

APA

Gao, S., Wei, Y., Li, C., Xie, B., Zhang, X., Cui, Y., & Dai, H. (2025). A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00374.2024

Vancouver

Gao S, Wei Y, Li C, Xie B, Zhang X, Cui Y, et al. A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14. American Journal of Physiology-Cell Physiology. 2025. doi:10.1152/ajpcell.00374.2024

BibTeX
@article{Gao2025,
  author = {Gao, Shuwei and Wei, Yanqiu and Li, Chen and Xie, Bingbing and Zhang, Xinran and Cui, Ye and Dai, Huaping},
  title = {A novel lncRNA ABCE1-5 regulates pulmonary fibrosis by targeting KRT14},
  journal = {American Journal of Physiology-Cell Physiology},
  year = {2025},
  doi = {10.1152/ajpcell.00374.2024}
}
Kostenlos starten →